2011

Founded

£87 million

Capital investment

100+

DUB targets explored

#1

In the DUB field

Commercializing expert research into

Dubs and Ubiquitin pathway

Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.